Amantadine treatment is an independent predictor of improved survival in Parkinson's disease

Neurology

Volumn 46, Issue 6, 1996, Pages 1551-1556

  Uitti, R J ^a   Rajput, A H ^b   Ahlskog, J E ^c   Offord, K P ^c   Schroeder, D R ^c   Ho, M M ^c   Prasad, M ^b   Rajput, A ^d   Basran, P ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE UPTAKE INHIBITOR; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMENTIA; DRUG MECHANISM; DRUG MIXTURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPROTECTION; PARKINSON DISEASE; PARKINSONISM; PREDICTION; PRIORITY JOURNAL; SURVIVAL;

EID: 0029884473     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.6.1551     Document Type: Article

References (36)

1. Lang AE, Blair RDG. Anticholinergic drugs and amantadine in the treatment of Parkinson's disease. In: Calne DB, ed. Drugs for the treatment of Parkinson's disease. New York: Springer-Verlag, 1989:307-323.
2. Bormann J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 1989; 166:591-592.
3. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 1985;82:2173-2177.
4. Turski L. Excitatory amino acid antagonists and Parkinson's disease. In: Rinne UK, Nagatsu T, Horowski R, eds. International Workshop Berlin Parkinson's Disease. Bussum, Netherlands: Medicom, 1991:97-112.
5. Greenamyre JT, O'Brien CF. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol 1991;48:977-981.
6. Uitti RJ, Ahlskog JE, Maraganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Neurology 1993;43:1918-1926.
7. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
8. Rajput AH, Uitti RJ, Basran P, Ho M, Rajput A, Offord K. Survival in parkinsonism on modern therapy [abstract]. Mov Disord 1992;7(Suppl 1):77.
9. Rajput AH, Stern W, Laverty WH. Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology 1984;34:991-996.
10. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. JASA 1958;53:457-481.
11. Bergstralh EJ, Offord KP. Conditional probabilities used in calculating cohort expected survival. Section of Biostatistics, Mayo Clinic, Technical Report Series No. 37, January 1988.
12. Fleming TR, Harrington DP. A class of hypothesis tests for one and two sample censored survival data. Comm Stat 1981; A10:763-794.
13. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Can Chemo Rep 1966;50:163-170.
14. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc Series B 1972;34:187-220.
15. Uitti RJ, Calne DB. Pathogenesis of idiopathic parkinsonism. Eur Neurol 1993;33(suppl 1):6-23.
16. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40(suppl 3):32-37.
17. Wichmann T, Bergman H, DeLong MR. The primate subthalamic nucleus. III. Changes in motor behavior and neuronal activity in the internal pallidum induced by subthalamic inactivation in the MPTP model of parkinsonism. J Neurophysiol 1994;72:521-530.
18. Rajput AH, Uitti RJ. Neurological disorders and services in Saskatchewan - a report based on provincial health care records. Neuroepidemiology 1988;7:145-151.
19. Rabey JM, Nissipeanu P, Korczyn AD. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neural Transm Park Dis Dement Sect 1992;4: 277-282.
20. Moryl E, Danysz W, Quack G. Potential antidepressive properties of amantadine, memantine, and bifemelane. Pharmacol Toxicol 1993;72:394-397.
21. Drake ME Jr, Pakalnis A, Denio LS, Phillips B. Amantadine hydrochloride for refractory generalized epilepsy in adults. Acta Neurol Belg 1991;91:159-164.
22. Erkulwater S, Pillai R. Amantadine and the end-stage dementia of Alzheimer's type. South Med J 1989;82:550-554.
23. Rytik PG, Eremin VF, Kvacheva ZB, et al. Susceptibility of primary human glial fibrillary acidic protein-positive brain cells to human immunodeficiency virus infection in vitro: anti-HIV activity of memantine. AIDS Res Hum Retroviruses 1991;7:89-95.
24. Botez MI, Young SN, Botez T, Pedraza OL. Treatment of heredodegenerative ataxias with amantadine hydrochloride. Can J Neurol Sci 1991;18:307-311.
25. Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 1989;46:676-680.
26. Gupta RC, Kadel WL. Methyl parathion acute toxicity: prophylaxis and therapy with memantine and atropine. Arch Int Pharm Ther 1990;305:208-221.
27. Lustig HS, Ahern KV, Greenberg DA. Antiparkinsonian drugs and in vitro excitotoxicity. Brain Res 1992;597:148-150.
28. Richter A, Fredow G, Loscher W. Antidystonic effects of the NMDA receptor antagonists memantine, MK-801 and CGP 37849 in a mutant hamster model of paroxysmal dystonia. Neurosci Lett 1991;133:57-60.
29. Schwarz M, Block F, Sontag KH. N-methyl-D-aspartate (NMDA)-mediated muscle relaxant action of memantine in rats. Neurosci Lett 1992;143:105-109.
30. Stoof JC, Booij J, Drukarch B. Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications? Clin Neurol Neurosurg 1992;94(Suppl): S4-S6.
31. Lupp A, Lucking CH, Koch R, Jackisch R, Feuerstein TJ. Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro. J Pharmacol Exp Ther 1992;263:717-724.
32. Jackisch R, Link T, Neufang B, Koch R. Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine: no evidence for direct dopaminomimetic or antimuscarinic properties. Arch Intl Pharm 1992;320:21-42.
33. Mercuri NB, Stratta F, Calabresi P, Bernardi G. Nomifensine but not amantadine increases dopamine-induced responses on rat substantia nigra zona compacta neurons. Neurosci Lett 1991;131:145-148.
34. Pellegrini JW, Lipton SA. Delayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicity. Ann Neurol 1993;33:403-407.
35. Greenamyre JT, Eller RV, Zhang Z, Ovadia A, Kurlan R, Gash DM. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol 1994;35:655-661.
36. Uitti RJ, Rajput AH, Ahlskog JE, et al. Amantadine treatment is an independent predictor of improved survival in parkinsonism [abstract]. Can J Neurol Sci 1993;20(Suppl 4):S235.